Literature DB >> 20097930

Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia.

Meenakshi Sundaram1, Shumei Zhong, Maroun Bou Khalil, Hu Zhou, Zhenghui G Jiang, Yang Zhao, Jahangir Iqbal, M Mahmood Hussain, Daniel Figeys, Yuwei Wang, Zemin Yao.   

Abstract

We have shown that expression of apolipoprotein (apo) C-III promotes VLDL secretion from transfected McA-RH7777 cells under lipid-rich conditions. To determine structural elements within apoC-III that confer to this function, we contrasted wild-type apoC-III with a mutant Ala23Thr originally identified in hypotriglyceridemia subjects. Although synthesis of [(3)H]glycerol-labeled TAG was comparable between cells expressing wild-type apoC-III (C3wt cells) or Ala23Thr mutant (C3AT cells), secretion of [(3)H]TAG from C3AT cells was markedly decreased. The lowered [(3)H]TAG secretion was associated with an inability of C3AT cells to assemble VLDL(1). Moreover, [(3)H]TAG within the microsomal lumen in C3AT cells was 60% higher than that in C3wt cells, yet the activity of microsomal triglyceride-transfer protein in C3AT cells was not elevated. The accumulated [(3)H]TAG in C3AT microsomal lumen was mainly associated with lumenal IDL/LDL-like lipoproteins. Phenotypically, this [(3)H]TAG fractionation profiling resembled what was observed in cells treated with brefeldin A, which at low dose specifically blocked the second-step VLDL(1) maturation. Furthermore, lumenal [(35)S]Ala23Thr protein accumulated in IDL/LDL fractions and was absent in VLDL fractions in C3AT cells. These results suggest that the presence of Ala23Thr protein in lumenal IDL/LDL particles might prevent effective fusion between lipid droplets and VLDL precursors. Thus, the current study reveals an important structural element residing within the N-terminal region of apoC-III that governs the second step VLDL(1) maturation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097930      PMCID: PMC3035516          DOI: 10.1194/jlr.M005108

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  46 in total

1.  Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.

Authors:  G Schonfeld; P K George; J Miller; P Reilly; J Witztum
Journal:  Metabolism       Date:  1979-10       Impact factor: 8.694

2.  Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.

Authors:  A Fredenrich; L M Giroux; M Tremblay; L Krimbou; J Davignon; J S Cohn
Journal:  J Lipid Res       Date:  1997-07       Impact factor: 5.922

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis.

Authors:  Meihui Pan; Jun-shan Liang Js; Edward A Fisher; Henry N Ginsberg
Journal:  J Biol Chem       Date:  2001-11-09       Impact factor: 5.157

5.  Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.

Authors:  Jeffrey S Cohn; Michel Tremblay; Rami Batal; Hélène Jacques; Claudia Rodriguez; George Steiner; Orval Mamer; Jean Davignon
Journal:  Atherosclerosis       Date:  2004-11       Impact factor: 5.162

6.  The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells.

Authors:  Junji Yamaguchi; Mary V Gamble; Donna Conlon; Jun-shan Liang; Henry N Ginsberg
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

7.  Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidation.

Authors:  Agnes Kulinski; Sabina Rustaeus; Jean E Vance
Journal:  J Biol Chem       Date:  2002-06-18       Impact factor: 5.157

8.  Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER.

Authors:  Viktoria Gusarova; Jeffrey L Brodsky; Edward A Fisher
Journal:  J Biol Chem       Date:  2003-09-05       Impact factor: 5.157

9.  Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells.

Authors:  Khai Tran; Gro Thorne-Tjomsland; Cynthia J DeLong; Zheng Cui; Jing Shan; Lynn Burton; James C Jamieson; Zemin Yao
Journal:  J Biol Chem       Date:  2002-06-13       Impact factor: 5.157

10.  Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Authors:  Jeffrey S Cohn; Bruce W Patterson; Kris D Uffelman; Jean Davignon; George Steiner
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  25 in total

Review 1.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

2.  Secretion of triacylglycerol-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase.

Authors:  Michelle Bamji-Mirza; Meenakshi Sundaram; Shumei Zhong; Erik F Yao; Robin J Parks; Zemin Yao
Journal:  J Lipid Res       Date:  2010-12-27       Impact factor: 5.922

Review 3.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

4.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

5.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

6.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

7.  Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.

Authors:  Wen Qin; Meenakshi Sundaram; Yuwei Wang; Hu Zhou; Shumei Zhong; Chia-Ching Chang; Sanjay Manhas; Erik F Yao; Robin J Parks; Pamela J McFie; Scot J Stone; Zhenghui G Jiang; Congrong Wang; Daniel Figeys; Weiping Jia; Zemin Yao
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

8.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

Review 9.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

10.  Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces.

Authors:  Nathan L Meyers; Libo Wang; Olga Gursky; Donald M Small
Journal:  J Lipid Res       Date:  2013-05-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.